TY - JOUR
T1 - Endothelial cell hypertrophy and microvascular proliferation in meningiomas are correlated with higher histological grade and shorter progression-free survival
AU - Ling, Catherine
AU - Pouget, Celso
AU - Rech, Fabien
AU - Pflaum, Robin
AU - Treffel, Mathilde
AU - Bielle, Franck
AU - Mokhtari, Karima
AU - Casse, Jean Matthieu
AU - Vignaud, Jean Michel
AU - Kalamarides, Michel
AU - Peyre, Matthieu
AU - Gauchotte, Guillaume
N1 - Publisher Copyright:
© 2016 American Association of Neuropathologists, Inc.
PY - 2016/12/1
Y1 - 2016/12/1
N2 - Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p=0.0004, and p=0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p=0.017, p=0.021, and p=0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p=0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.
AB - Microvascular proliferation (MVP) is a hallmark of glioblastoma. Endothelial cell hypertrophy (ECH), also known as endothelial hyperplasia, is correlated with a shorter survival of patients with gliomas. However, the prognostic value of these 2 morphological features has not been studied in meningiomas. The aim of this study was to evaluate the prognostic value of angiogenesis in meningiomas, most notably ECH, MVP, and microvascular density, which were evaluated using immunohistochemistry with antibodies against CD34 and CD105 (a marker of neovascularization) in a series of 139 meningiomas. ECH, MVP, and CD105 immunoreactivity were significantly correlated with higher histological grades (p < 0.0001, p=0.0004, and p=0.0003, respectively). ECH and MVP but not CD105 immunoreactivities were significantly correlated with a shorter progression-free survival time (PFS) (p=0.017, p=0.021, and p=0.137, respectively). In Cox multivariate analysis, ECH was an independent predictor of shorter PFS (p=0.028). Therefore, ECH and MVP are markers of shorter PFS in meningiomas and are significantly correlated with grade. These findings give insight into the use of anti-angiogenic therapies. Further studies are needed to determine whether these markers could allow us to identify patients who could benefit from anti-angiogenic therapies.
KW - CD105
KW - CD34
KW - Endothelial cell hypertrophy
KW - Meningioma
KW - Microvascular proliferation
KW - Microvessel density
KW - Vascularization
UR - http://www.scopus.com/inward/record.url?scp=85021853869&partnerID=8YFLogxK
U2 - 10.1093/jnen/nlw095
DO - 10.1093/jnen/nlw095
M3 - Article
C2 - 27807004
AN - SCOPUS:85021853869
SN - 0022-3069
VL - 75
SP - 1160
EP - 1170
JO - Journal of Neuropathology and Experimental Neurology
JF - Journal of Neuropathology and Experimental Neurology
IS - 12
ER -